Recent Evidence on the Use of Tiotropium Bromide in Pediatric Asthma: Summary Results of Eight Clinical Trials


Recent Evidence on the Use of Tiotropium Bromide in Pediatric Asthma: Summary Results of Eight Clinical Trials
Ricardo Cardona-Villa, MD, MSc1,2,* Manuela Tejada-Giraldo, BioEngr, MSc1
1Grupo Alergología Clínica y Experimental (GACE), Universidad de Antioquia, Medellín, Colombia
*,2IPS Universitaria - Servicio de Alergología Clínica, Universidad de Antioquia, Carrera 51A No. 62-42, Medellin, Colombia



Purpose of Review To collect the existing information on tiotropium as an add-on treat- ment for asthma in children and adolescents.
Recent Findings The use of tiotropium bromide in children between 1 and 6 years old. Summary Asthma is a disease that can be difficult to control. For the treatment of this, there is a combination of medications, but often complete control of the disease is not achieved. The addition of tiotropium, a long-acting muscarinic antagonist, to treatment with inhaled corticosteroids has been recommended to improve lung function in adults and adolescents who have uncontrolled asthma. Here we present a review of the eight clinical trials that show the use of tiotropium in pediatric patients with asthma. The results demonstrate efficacy in improving lung function (evaluated with different parameters), in both children and adolescents; it also shows the safety of the drug in short and long-term uses.



DOI 10.1007/s40521-018-0194-0

Comentarios

Entradas populares de este blog

ICON: Diagnosis and management of allergic conjunctivitis. Miércoles 25 de marzo

Instructivo para la vigilancia en salud pública intensificada de infección respiratoria aguda asociada al nuevo coronavirus 2019 (COVID-19).

BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. Martes 14 de abril